Treatment(s) already received-Orchiectomy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Orchiectomy Posts on Medivizor

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Posted by on Aug 21, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of testosterone replacement therapy (TRT) in men who had definitive treatment for prostate cancer. The authors concluded that TRT was not associated with a higher risk of recurrence in these patients. Some background Prostate cancer (PCa) is commonly fueled by the sex hormone testosterone....

Read More

Looking for men with castration-resistant prostate cancer to try 177Lu-PSMA-617

Posted by on Feb 24, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is looking at the effectiveness of 177Lu-PSMA-617 in the treatment of castration-resistant (tumor grows even with hormone therapy) prostate cancer. The main outcome to be measured is overall survival.  The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...

Read More

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

Posted by on Jan 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the links between prostate specific antigen (PSA, a protein present in prostate cancer) and survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. This studty concluded that PSA response after cabazitaxel treatment is associated with improved...

Read More

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Searching for men with metastatic castration-resistant prostate cancer to test new immunotherapy combination

Posted by on Mar 6, 2017 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial aims to evaluate the benefit of adding tremelimumab to durvalumab, two new types of immunotherapy, for metastatic castration-resistant prostate cancer. The main outcome to be investigated is treatment response. The trial is recruiting in several locations in Canada.   The details Metastatic...

Read More

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...

Read More

What treatments are available for patients progressing after primary and secondary hormone therapy?

Posted by on Jul 29, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) progressing after treatment with abiraterone acetate (Zytiga). Chemotherapy with docetaxel (Taxotere) was the most common subsequent therapy. Authors concluded that patients with mCRPC who progress after AA may still benefit from subsequent...

Read More

Decline in circulating tumor cells during treatment associated with better survival

Posted by on Jun 27, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment.  Some background Metastatic castration-resistant prostate...

Read More

Potential predictor of treatment outcomes for metastatic castration-resistant prostate cancer

Posted by on Jun 17, 2016 in Prostate cancer | 0 comments

In a nutshell This study analyzed predictors of treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that testosterone levels before treatment can help predict overall survival in men with mCRPC.  Some background Hormone therapy is the standard of care for advanced prostate cancer, including...

Read More

Searching for men with progressive metastatic prostate cancer to test combinations of newly approved treatments

Posted by on Jun 6, 2016 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...

Read More